(Q35569069)

8 August 2017

1 reference

title

Specific chemotherapy of Chagas disease: controversies and advances (English)

1 reference

8 August 2017

0 references

1 reference

2

Roberto Docampo

1 reference

8 August 2017

Julio A. Urbina

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14580960

25 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14580960

25 March 2024

publication date

1 November 2003

1 reference

full work available at URL

8 August 2017

https://api.elsevier.com/content/article/PII:S1471492203002411?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

https://api.elsevier.com/content/article/PII:S1471492203002411?httpAccept=text/plain

25 March 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

25 March 2024

published in

Trends in Parasitology

1 reference

8 August 2017

volume

19

1 reference

8 August 2017

issue

11

1 reference

8 August 2017

page(s)

495-501

1 reference

Reaching maturity - 25 years of the TDR.

8 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

Trypanosomiasis control: surmounting diminishing returns

25 March 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

Immunological control of Trypanosoma cruzi infection and pathogenesis of Chagas' disease.

25 March 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

Chagas disease etiology: autoimmunity or parasite persistence?

25 March 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

Parasite persistence in the aetiology of Chagas disease

25 March 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

Sensitivity of parasites to free radical damage by antiparasitic drugs

25 March 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

Criteria of Chagas disease cure

25 March 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

Specific chemotherapy of Chagas disease: a comparison between the response in patients and experimental animals inoculated with the same strains

25 March 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

Immunological and clinical evaluation of chagasic patients subjected to chemotherapy during the acute phase of Trypanosoma cruzi infection 14-30 years ago

25 March 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

Experimental chemotherapy against Trypanosoma cruzi infection: essential role of endogenous interferon-gamma in mediating parasitologic cure

25 March 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease

25 March 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

Treatment of Trypanosoma cruzi infection in the undetermined phase. Experience and current guidelines of treatment in Argentina

25 March 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

Evaluation of an specific treatment for Trypanosoma cruzi in children, in the evolution of the indeterminate phase

25 March 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

Treatment of Trypanosoma cruzi-infected children with nifurtimox: a 3 year follow-up by PCR.

25 March 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

Myocardial parasite persistence in chronic chagasic patients

25 March 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

Persistent infections in chronic Chagas' disease patients treated with anti-Trypanosoma cruzi nitroderivatives

25 March 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

Parasite persistence in treated chagasic patients revealed by xenodiagnosis and polymerase chain reaction

25 March 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives.

25 March 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

Specific treatment of Chagas disease: current status and new developments

25 March 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

Chemotherapy of Chagas disease

25 March 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up

25 March 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

Recent developments in the chemotherapy of Chagas disease.

25 March 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

A critical review on Chagas disease chemotherapy

25 March 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

Treatment of chronic Chagas' disease with itraconazole and allopurinol.

25 March 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: the regression and prevention of electrocardiographic abnormalities during 9 years of follow-up

25 March 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains

25 March 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease

25 March 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

In vitro antiproliferative effects and mechanism of action of the new triazole derivative UR-9825 against the protozoan parasite Trypanosoma (Schizotrypanum) cruzi

25 March 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

Potent anti-Trypanosoma cruzi activities of oxidosqualene cyclase inhibitors

25 March 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

Squalene synthase as a chemotherapeutic target in Trypanosoma cruzi and Leishmania mexicana

25 March 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

The major cysteine proteinase of Trypanosoma cruzi: a valid target for chemotherapy of Chagas disease

25 March 2024

38

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

Cysteine proteinases of trypanosome parasites: novel targets for chemotherapy.

25 March 2024

39

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection

25 March 2024

40

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

Synthesis and structure-activity relationship study of potent trypanocidal thio semicarbazone inhibitors of the trypanosomal cysteine protease cruzain

25 March 2024

41

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

25 March 2024

The acidocalcisome

42

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

Therapeutic approaches to bone diseases

25 March 2024

43

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase

25 March 2024

44

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

Bisphosphonates as chemotherapeutic agents against trypanosomatid and apicomplexan parasites

25 March 2024

45

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

[Ineffectiveness of allopurinol in patients in the acute phase of Chagas disease]

25 March 2024

47

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

Efficient identification of inhibitors targeting the closed active site conformation of the HPRT from Trypanosoma cruzi

25 March 2024

49

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

Enzymes of the trypanothione metabolism as targets for antitrypanosomal drug development

25 March 2024

50

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

Inhibitors of dihydrofolate reductase in Leishmania and trypanosomes

25 March 2024

51

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi

25 March 2024

52

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics.

25 March 2024

53

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

Autoimmunity in chagas disease cardiomyopathy: Fulfilling the criteria at last?

25 March 2024

54

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

Pathogenesis of Chagas heart disease: role of autoimmunity

25 March 2024

55

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

Parasitological cure of Chagas disease: is it possible? Is it relevant?

25 March 2024

56

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

Severity of chronic Chagas disease is associated with cytokine/antioxidant imbalance in chronically infected individuals

25 March 2024

57

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.001

25 March 2024

Identifiers

1 reference

8 August 2017

1 reference